US-based medical device company QT Imaging Holdings Inc (OTCQB: QTIH) revealed on Monday that it has entered into an exclusive distribution agreement with Gulf Medical Co for the supply of its FDA-cleared Breast Acoustic CT scanner and subscriptions to the QTI Cloud Platform in Saudi Arabia.
The agreement sets minimum orders of five scanners per quarter beginning in the first quarter of 2026 through to the end of 2028, totalling at least 60 scanners and generating revenue of more than USD33m. Gulf Medical will also distribute QTI's AI-enabled cloud platform, designed to enhance breast health imaging through automated classification and second-read decision support.
QTI's non-invasive 3D breast imaging technology, which avoids compression, contrast agents and radiation, is particularly relevant in Saudi Arabia where genetic predispositions, including BRCA1 and BRCA2 mutations, contribute to higher breast cancer incidence among women aged 40 to 59.
Founded in 1983, Gulf Medical Co, part of the Al-Naghi Group, is a leading distributor of medical technologies across the Middle East.
QT Imaging Holdings is a US-based medical device company focused on safe, affordable and patient-centered imaging systems using low-frequency sound waves.
QT Imaging signs exclusive USD33m distribution deal with Gulf Medical in Saudi Arabia
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
Covalon Technologies secures DTC eligibility to expand US investor access
Navamedic ASA secures final approvals for Flexilev in OraFID across Nordic markets
Oncopeptides partners with SD Pharma to expand Pepaxti access in Spain
Aptar launches bio-based nasal spray pump with Haleon's Otrivin brand
MAP Medical agrees distribution deal with Metrix-Secure
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Predictmedix AI launches mobile diabetes screening platform in India
Navamedic's medical device OraFID approved as primary package for a pharmaceutical product
Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions
Immuno Cure and PharmaJet collaborate for novel HIV therapeutic DNA vaccine advancement